Analysts Set Expectations for VIR Q1 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Leerink Partnrs issued their Q1 2025 earnings estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz expects that the company will earn ($1.09) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2025 earnings at ($3.80) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($0.60) EPS.

Other equities analysts have also recently issued reports about the stock. Barclays lowered their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. boosted their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, January 10th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.83.

Vir Biotechnology Trading Down 2.8 %

Shares of NASDAQ VIR opened at $10.23 on Wednesday. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -2.61 and a beta of 0.51. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The stock has a 50-day moving average price of $8.27 and a two-hundred day moving average price of $8.37.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. Vir Biotechnology’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period last year, the firm posted ($1.22) EPS.

Institutional Trading of Vir Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of VIR. Charles Schwab Investment Management Inc. raised its holdings in shares of Vir Biotechnology by 13.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after acquiring an additional 136,087 shares during the last quarter. State Street Corp raised its stake in shares of Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after purchasing an additional 530,645 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in shares of Vir Biotechnology in the second quarter valued at approximately $1,780,000. Point72 Hong Kong Ltd boosted its position in shares of Vir Biotechnology by 180.6% during the second quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock valued at $174,000 after buying an additional 12,598 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Vir Biotechnology by 94.6% during the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after buying an additional 606,804 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 14,786 shares of company stock valued at $170,172 in the last quarter. 15.60% of the stock is currently owned by company insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).